INNOVOTEX

Biotechnology Research • Austin, Texas, United States • 1-10 Employees

Company overview

Headquarters	3800 N Lamar Blvd, Austin, Texas 78756, US
Website	innovotexinc.com
NAICS	541714
Employees	1-10

Key Contact at INNOVOTEX

Jonathan Arambula

CEO, President and Director

INNOVOTEX Email Formats

INNOVOTEX uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@innovotexinc.com), used 100% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@innovotexinc.com	100%

About INNOVOTEX

InnovoTEX is an oncology therapeutic company developing its proprietary platform of uniquely designed novel assets. We identified a lead clinical candidate, NOVO-111, that induces ribosomal biosynthesis stress to activate wt-p53 and circumvent platinum resistance in wt-p53 refractory cancers, including ovarian cancer. Secondary candidates are in early development for multiple solid tumor indications. Our exclusive IP portfolio is licensed from UT Austin and MD Anderson Cancer Center, which supports our strong collaboration with each institution for continued development work. We are in early conversations with large pharma for potential milestone partnerships that could result in an early exit within 2-5 years.

INNOVOTEX revenue & valuation

Annual revenue	$342,220
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$1,100,000
Total funding	No funding